Precision diagnosis and individual prediction of early lung cancer based on multidimensional omics

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100055073

Enrollment

Unknown

Registered

2021-12-31

Start date

2022-01-01

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Gold Standard:Histopathological diagnosis.

Index test:Images&#32

of&#32

low-dose&#32

CT,&#32

laboratory&#32

test&#32

indexes,&#32

genetic&#32

testing&#32

indexes.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Low-dose CT lung cancer screening patients with pulmonary nodules; 2. After surgical treatment, there are preoperative test indicators and postoperative histopathological results (including genetic test results).

Exclusion criteria

Exclusion criteria: 1. A history of cancer in the past 5 years (except non-melanoma skin cancer, cervical carcinoma in situ, and localized prostate cancer); 2. Inability to tolerate possible lung cancer resection; 3. Suffering from a serious life-threatening disease.

Design outcomes

Primary

Measure	Time frame
Histopathological diagnosis of pulmonary nodule;Images of low-dose CT;Laboratory test indexes;Genetic testing indexes;Accuracy, sensitivity, specificity;	—

Countries

China

Contacts

Public ContactZhou Peng

Sichuan Cancer Hospital

penghyzhou@126.com+86 13880227322

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026